Colorectal Cancer Therapeutics strategies and Product Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Colorectal Cancer Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Colorectal Cancer Report Coverage 11
2.2 Anal Cancer - Overview 11
2.3 Rectal Cancer - Overview 11
2.4 Colorectal Cancer - Overview 11
3 Therapeutics Development 12
3.1 Anal Cancer 12
3.2 Rectal Cancer 16
3.3 Colorectal Cancer 18
4 Therapeutics Assessment 56
4.1 Anal Cancer 56
4.2 Rectal Cancer 63
4.3 Colorectal Cancer 71
5 Companies Involved in Therapeutics Development 100
5.1 Anal Cancer 100
5.2 Rectal Cancer 108
5.3 Colorectal Cancer 114
6 Dormant Projects 241
6.1 Anal Cancer 241
6.2 Rectal Cancer 241
6.3 Colorectal Cancer 242
7 Discontinued Products 261
7.1 Anal Cancer 261
7.2 Colorectal Cancer 261
8 Product Development Milestones 265
8.1 Anal Cancer 265
8.2 Rectal Cancer 278
8.3 Colorectal Cancer 280
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/colorectal-cancer-therapeutics-strategies-and-product-pipeline-review-2017/250073

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250073

Latest News

The Latest: S. Korean diva sings at North Korean volcano

Sep 20, 2018

SEOUL, South Korea — The Latest on the summit between North Korean leader Kim Jong Un and South Korean President Moon Jae-in (all times local): 8 p.m. A South Korean pop singer has belted out a beloved Korean folk song in front of North Korean leader Kim Jong Un and South Korean President Moon Jae-in at a crater lake atop a volcano North Korea considers as sacred. Singer Ali was among the South Koreans who joined the leaders on a trip to Mount Paektu on the North Korean-Chinese border hours before they returned home on Thursday after three days of...

The Latest: Trump welcomes 'tremendous progress' with NKorea

Sep 20, 2018

PYONGYANG, North Korea — The Latest on the summit between North Korean leader Kim Jong Un and South Korean President Moon Jae-in (all times local): 11 p.m. U.S. President Donald Trump says "we're making tremendous progress" with North Korea, after an inter-Korean summit offered some apparent concessions from the North on its weapons program. Trump told reporters Wednesday that "we had very good news" out of the summit, where leader Kim Jong Un promised to dismantle a rocket launch site and also agreed to dismantle its main nuclear site if the U.S. takes unspecified corresponding measures. Trump didn't indicate in...

China reaches out to US over demand for media registration

Sep 20, 2018

BEIJING — China has reached out to the U.S. over reports that the Department of Justice has ordered two top Chinese state-run news outlets to register as foreign agents, a spokesman said Wednesday, adding that Beijing opposed "politicizing" the role of the media. Foreign Ministry spokesman Geng Shuang said that Beijing had "contacted and communicated" with the U.S. side over the issue, but gave no details. "Media serve as an important bridge and link to help the people from different countries to better understand and communicate with each other," Geng told reporters at a daily briefing. "We should provide convenience...

Summit may be the grand theater Kim needs to show his people

Sep 20, 2018

SEOUL, South Korea — If North Korean leader Kim Jong Un was searching for the perfect propaganda set piece, something designed to show his people that he's a strong leader pushing inexorably for the long-delayed, long-promised prosperity they deserve, then visiting South Korean President Moon Jae-in might be providing him with a unique opportunity. Moon believes that his deep engagement with North Korea is crucial after last year's fears of war, when Washington reacted with fury to a torrent of ever-more-powerful North Korean weapons tests. He argues better ties with North Korea will help South Koreans, and the region, by...

Moonstruck Japan tycoon to blast off on 1st SpaceX trip

Sep 20, 2018

TOKYO — The Japanese billionaire who Tesla chief Elon Musk says plans to blast off on the first-ever private commercial space trip aboard the SpaceX Big Falcon Rocket often makes headlines in Japan. The SpaceX mission, set for takeoff in 2023, is just the latest exploit in tycoon Yusaku Maezawa's colorful and ambitious career: ___ FASHION BRAND Maezawa, 42, is the chief executive of Start Today Co., which he founded in 1998 as a CD sales business when he was still in his 20s. The company pioneered e-commerce in Japan and now runs the popular fashion mall Zozotown, selling various,...

Sign up now!